SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:oru-70216"
 

Sökning: onr:"swepub:oai:DiVA.org:oru-70216" > A Swedish nationwid...

  • Demirbüker, S. SaferDepartment of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)

A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5)

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • Sage Publications,2018
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-70216
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-70216URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:vet swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies:BiogenNovartis  Merck Serono  Teva  Sanofi Genzyme  Genzyme
  • Background: Dimethyl fumarate (DMF) is an oral therapy for relapsing-remitting multiple sclerosis (RRMS), which has been included in the Swedish post-market surveillance study “Immunomodulation and Multiple Sclerosis Epidemiology 5” (IMSE 5) in order to monitor and determine the long-term safety and effectiveness in a real-world setting.Objectives: To follow-up the long-term safety and effectiveness of DMF in a real-world setting.Methods: MS patients are registered into the nationwide Swedish Neuro Registry (NeuroReg) in Sweden. The IMSE 5 study obtains descriptive data of adverse events (AEs), Extended Disability Status Scale (EDSS), Multiple Sclerosis Severity Scale (MSSS), Symbol Digit Modalities Test (SDMT), Multiple Sclerosis Impact Scale (MSIS-29), European Quality of Life - Five Dimensions Test (EQ-5D) and Visual Analog Scale (VAS) from NeuroReg. Drug survival was measured using the Kaplan-Meier curve and effectiveness measures were assessed using the Wilcoxon Signed Rank Test.Results: 2010 DMF-treated patients have been included in the IMSE 5 study between March 2014 and April 2018. 73 % were female and the mean age at treatment start was 40.6 years. The mean treatment duration was 22.3 months. 92 % of the patients had RRMS with 2 % missing data on MS phenotype. Most patients switched from interferon and glaimer acetat (41 %) and 24 % of the patients were treatment naïve (13 % were missing data on prior treatment). The overall one year drug survival was 74 % and 889 patients terminated their treatment at some point. Most patients (39 %) switched to rituximab (15 % have no new treatment registered). The most common reason for discontinuation was AEs (53 %) and lack of effect (29 %). 227 (11 %) patients have continued treatment for ≥36 months. In patients treated with DMF continuously for ≥24 months (n=918), significant improvements in mean values at 24 months of treatment compared to mean baseline values have been noted for EDSS (1.9 ± 1.6 to 1.6 ± 1.6, n=196); MSSS (2.5 ± 2.4 to 2.0 ± 2.0, n=145); SDMT (52.6 ± 11.0 to 53.8 ± 11.7, n=315); MSIS-29 Psychological Subscale (26.3 ± 22.8 to 21.8 ± 20.6, n=337); and EQ-5D (0.76 ± 0.23 to 0.81 ± 0.20, n=284).Conclusions: NeuroReg proves to function well as a post-marketing drug surveillance platform, providing data regarding drug effectiveness and AEs. A longer follow-up period is needed to assess the real-world effectiveness and safety of DMF.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Kågström, S.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Fält, A.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Berglund, A.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Hillert, J.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Nilsson, P.Department of Neurology, Lund University, Lund, Sweden (författare)
  • Dahle, C.Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden (författare)
  • Svenningsson, A.Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden (författare)
  • Lycke, J.Department of Clinical Neuroscience and Rehabilitation, University of Gothenburg, Gothenburg, Sweden (författare)
  • Landtblom, A. -MDepartment of Neuroscience, Uppsala University, Uppsala, Sweden (författare)
  • Burman, J.Department of Neuroscience, Uppsala University, Uppsala, Sweden (författare)
  • Sundström, P.Department of Clinical Neuroscience, Umeå University, Umeå, Sweden (författare)
  • Martin, C.Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden (författare)
  • Gunnarsson, Martin,1973-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Neurology(Swepub:oru)mign (författare)
  • Piehl, F.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Olsson, T.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden (författare)
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SwedenDepartment of Neurology, Lund University, Lund, Sweden (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Multiple Sclerosis Journal: Sage Publications24:Suppl. 2, s. 701-7021352-45851477-0970

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy